FemmeLoop

FemmeLoop is a women's health technology company focused on transforming the management of perimenopause and menopause through an integrated digital health platform and at-home diagnostic tools. In partnership with Burst Diagnostics, the company is developing a low-cost, multiplexed urine-based assay that quantitatively measures key hormones, including estradiol, progesterone, follicle-stimulating hormone (FSH), and luteinizing hormone (LH), using a smartphone-connected reader. The platform combines these biological insights with symptom tracking to provide personalized health data, enabling women and their healthcare providers to establish hormone baselines and track fluctuations over time. By bridging the gap in menopause care with continuous, data-driven monitoring, FemmeLoop aims to empower women with clarity and control during their midlife transition. The company's approach leverages advanced immunoassay technology and AI-driven analytics to deliver clinical-grade insights in a convenient, at-home format. FemmeLoop is currently advancing its technology through research collaborations and federal funding, including a Phase I SBIR grant from the National Institutes of Health.